Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Profit After Tax: 2020-2025

Historic Profit After Tax for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$10.9 million.

  • Insight Molecular Diagnostics' Profit After Tax rose 19.56% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 40.87%. This contributed to the annual value of -$60.7 million for FY2024, which is 118.36% down from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Profit After Tax is -$10.9 million, which was down 11.41% from -$9.7 million recorded in Q2 2025.
  • Insight Molecular Diagnostics' 5-year Profit After Tax high stood at $6.0 million for Q1 2023, and its period low was -$45.0 million during Q4 2022.
  • Moreover, its 3-year median value for Profit After Tax was -$9.1 million (2024), whereas its average is -$10.3 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first plummeted by 468.79% in 2021, then soared by 157.90% in 2023.
  • Over the past 5 years, Insight Molecular Diagnostics' Profit After Tax (Quarterly) stood at -$35.9 million in 2021, then fell by 25.34% to -$45.0 million in 2022, then spiked by 64.44% to -$16.0 million in 2023, then crashed by 109.55% to -$33.5 million in 2024, then increased by 19.56% to -$10.9 million in 2025.
  • Its Profit After Tax was -$10.9 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$6.7 million in Q1 2025.